Allergen immunotherapy is currently the only one method of cause treatment of the IgE-dependent allergic diseases. Sublingual immunotherapy (SLIT) is the method which allows to give allergens via alternative oral route in patients home. Due to possibility of avoiding injection this therapy offers better relationship with pediatric patient. However efficacy and safety of sublingual immunotherapy are still important issues, especially in asthmatic children. The purpose of the trial is to asses the efficacy and safety of sublingual annual immunotherapy in children with bronchial asthma and/or allergic rhinitis allergic to house dust mites.
Age
6–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
patients with bronchial asthma and/or allergic rhinitis allergic to house dust mites first diagnosed at least 2 years before the study
You may not be if
active respiratory tract infection requiring antibiotic treatment within 4 weeks before the study
hospitalisation due to asthma exacerbation during the 3 months before the first visit
known contraindications of SIT according to the EAACI
previous allergen immunotherapy
use of systemic corticosteroids
other clinically significant pulmonary, hematologic, hepatic, gastrointestinal, renal, endocrine, neurologic, cardiovascular, and/or mental diseases or malignancy that either put the patient at risk when participating in the study or could influence the results of the study
Clareo Health | Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites
